Tirzepatide
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Eli Lilly · Phase 2 · Not yet recruiting · Enrollment 224
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo Comparator: Placebo | n/r | n/r | n/r | n/r | n/r |
| Placebo + Tirzepatide 5 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo + Tirzepatide 10 mg | n/r | n/r | n/r | n/r | n/r |
| NA-931 60mg to NA-931 150 mg + no Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| NA-931 60 mg + Tirzepatide 5 mg | n/r | n/r | n/r | n/r | n/r |
| NA-931 120 mg + Tirzepatide 5 mg | n/r | n/r | n/r | n/r | n/r |
| NA-931 150 mg + no Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| NA-931 150 mg + Tirzepatide 2.5 mg | n/r | n/r | n/r | n/r | n/r |
| NA-931 150 mg + Tirzepatide 5 mg | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.